Probiotic Strain LPB27 Recognised in Nature Supplement

26 December 2025

KUALA LUMPUR: The Nature supplement showcases research exploring the potential of LPB27 and Bifidobacterium breve 207-1 in supporting digestive and metabolic health. Both strains have already been successfully incorporated into multiple Life-space products and are highly valued by consumers worldwide.

The inclusion of Life-space's proprietary strains in a prestigious Nature publication underscores the brand’s robust scientific capabilities. Currently, the Life-space Global Microbiome Centre oversees an end-to-end research ecosystem encompassing strain isolation, genome sequencing, in vitro testing, and animal studies.

With over ten years of experience in probiotic research and development, Life-space remains dedicated to a consumer-focused approach. The brand concentrates on personalised health solutions across the entire life cycle, developing targeted probiotic products for infants, children, adults, seniors, and women during pregnancy and lactation.

The scientific team at the Life-space Global Microbiome Centre comprises experts from world-renowned universities and authoritative institutions, including the University of Aberdeen, Wageningen University, Sun Yat-sen University, the Chinese Academy of Sciences, and IFREMER (French Research Institute for Exploitation of the Sea).

Collaborating with over fifty international research organisations and leading strain suppliers, Life-space ensures that every step, from strain screening and functional validation to production—is grounded in rigorous science to guarantee product efficacy and safety.

From functional strains and formula development to sensory evaluation, raw material control, dosage form innovation, and "Live-bac" packaging technology, Life-space has established a comprehensive R&D infrastructure. In the highly competitive probiotic sector, such deep vertical integration remains a rare and valuable advantage.

Life-space has achieved significant milestones in proprietary strain development, including multiple PCT international patents and the commercial application of "star" strains. In terms of product innovation, the brand has launched high-survivability tablets and synergistic formulations, with numerous technical achievements published in leading international journals.

Zhe Xiaolei, Head of R&D at the Life-space Global Microbiome Centre, stated, "We have successfully commercialised several self-developed strains. Among them, LPB27 is a flagship strain capable of high-activity colonisation and repairing the intestinal basement membrane."

Recognition by Nature affirms Life-space’s years of dedicated effort in probiotic research. Moving forward, the company will continue to leverage its comprehensive scientific research system to build a strong technological moat, consistently safeguarding consumer health worldwide.